GSK plc (LON:GSK - Get Free Report) insider Jonathan Symonds acquired 1,350 shares of the stock in a transaction that occurred on Friday, June 20th. The shares were bought at an average price of GBX 1,435 ($19.43) per share, with a total value of £19,372.50 ($26,228.68).
GSK Price Performance
Shares of GSK stock traded down GBX 33.16 ($0.45) during trading on Monday, reaching GBX 1,403 ($19.00). The company's stock had a trading volume of 10,733,926 shares, compared to its average volume of 14,536,212. The company has a current ratio of 0.81, a quick ratio of 0.73 and a debt-to-equity ratio of 114.64. The stock has a market capitalization of £56.93 billion, a P/E ratio of 22.66, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. GSK plc has a one year low of GBX 1,242.50 ($16.82) and a one year high of GBX 1,678.68 ($22.73). The stock has a 50-day moving average price of GBX 1,428.18 and a two-hundred day moving average price of GBX 1,413.92.
GSK (LON:GSK - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The company reported GBX 44.90 ($0.61) EPS for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. As a group, sell-side analysts anticipate that GSK plc will post 175.980975 EPS for the current fiscal year.
Analyst Ratings Changes
A number of brokerages recently issued reports on GSK. JPMorgan Chase & Co. reissued an "underweight" rating on shares of GSK in a report on Friday, March 28th. Shore Capital reiterated a "buy" rating on shares of GSK in a research report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of GBX 1,862.50 ($25.22).
Get Our Latest Stock Report on GSK
About GSK
(
Get Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Featured Stories
Before you consider GSK, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.
While GSK currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
